201 related articles for article (PubMed ID: 26671532)
1. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity.
Xu M; Jin H; Chen Z; Xie W; Wang Y; Wang Y; Wang M; Zhang J; Acheampong DO
Biotechnol Prog; 2016 Mar; 32(2):294-302. PubMed ID: 26785424
[TBL] [Abstract][Full Text] [Related]
3. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
4. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
5. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
6. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
7. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
8. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.
Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC
Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782
[TBL] [Abstract][Full Text] [Related]
9. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
12. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
Lu D; Zhang H; Koo H; Tonra J; Balderes P; Prewett M; Corcoran E; Mangalampalli V; Bassi R; Anselma D; Patel D; Kang X; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2005 May; 280(20):19665-72. PubMed ID: 15757893
[TBL] [Abstract][Full Text] [Related]
13. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity.
Cheng WJ; Lin SY; Chen M; Chen LC; Ho HO; Chuang KH; Sheu MT
Int J Nanomedicine; 2021; 16():4017-4030. PubMed ID: 34140769
[TBL] [Abstract][Full Text] [Related]
14. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
Shibuya K; Komaki R; Shintani T; Itasaka S; Ryan A; Jürgensmeier JM; Milas L; Ang K; Herbst RS; O'Reilly MS
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1534-43. PubMed ID: 17889445
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
17. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
18. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
19. Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects.
Yu Y; Lee P; Ke Y; Zhang Y; Chen J; Dai J; Li M; Zhu W; Yu GL
Biochem Biophys Res Commun; 2013 Jul; 436(3):543-50. PubMed ID: 23770369
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Gule MK; Chen Y; Sano D; Frederick MJ; Zhou G; Zhao M; Milas ZL; Galer CE; Henderson YC; Jasser SA; Schwartz DL; Bankson JA; Myers JN; Lai SY
Clin Cancer Res; 2011 Apr; 17(8):2281-91. PubMed ID: 21220477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
